Efruxifermin

Efruxifermin Reverses MASH Compensated Cirrhosi...

Efruxifermin, a long‐acting Fc‐fusion FGF21 ana...

Promising MASH Therapies Under Develpment - Hua...

Efruxifermin in Compensated Cirrhosis due to NA...

A Global Disease, A Pioneering Treatment NASDAQ...

- CONFIDENTIAL - 3 INTRODUCING EFRUXIFERMIN Efr...

Efruxifermin Reverses MASH Compensated Cirrhosi...

Efruxifermin for Nonalcoholic Steatohepatitis C...

Pre-dose efruxifermin (EFX) concentrations over...

Efruxifermin in Compensated Cirrhosis due to NA...

11_slide003.gif

Efruxifermin combined with a GLP-1 receptor ago...

Efruxifermin in non-alcoholic steatohepatitis: ...

Efruxifermin, a long‐acting Fc‐fusion FGF21 ana...

Schematic of efruxifermin structure. (adapted f...

Efruxifermin for NASH Clinical Trial 2024 | Power

Akero's Efruxifermin Shows Promise in MASH, Boo...

Akero Therapeutics on LinkedIn: #efruxifermin #...

Efruxifermin, a long‐acting Fc‐fusion FGF21 ana...

Can Efruxifermin Benefit MASH Patients? - Patie...

Akero Therapeutics | EFX for MASH | Fc-FGF21 Fu...

Akero's Efruxifermin Shows Promise in MASH, Boo...

Efruxifermin Led to NASH Resolution, Fibrosis I...

Efruxifermin in Compensated Cirrhosis due to NA...

Exhibit 99.1

Efruxifermin | Fc-FGF21 Fusion Protein | MedChe...

89bio (ETNB) Investor Presentation - Slideshow ...

Conquest Research on LinkedIn: Efruxifermin Gra...

- CONFIDENTIAL - 3 INTRODUCING EFRUXIFERMIN Efr...

Slide 3

S3-E54.2 - Presentation on Efruxifermin in NASH...

Amplifying Impact: Efruxifermin Plus GLP-1RA El...

Akero Therapeutics | EFX for MASH | Fc-FGF21 Fu...

Schematic of efruxifermin structure. (adapted f...

2375240-92-7 | Efruxifermin | ChemScene